Rose T. Ajamie

Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine

Lawrence M. Gelbert, Shufen Cai, Xi Lin et al. · Investigational New Drugs · 2014 · 565 citations · Full text

Medicine, Oncology, Pharmacology +17

Brain Exposure of Two Selective Dual CDK4 and CDK6 Inhibitors and the Antitumor Activity of CDK4 and CDK6 Inhibition in Combination with Temozolomide in an Intracranial Glioblastoma Xenograft

Thomas J. Raub, Graham N. Wishart, Palaniappan Kulanthaivel et al. · Drug Metabolism and Disposition · 2015 · 281 citations

Medicine, Oncology, Pharmacology +17

LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft models

S. Betty Yan, Victoria L. Peek, Rose T. Ajamie et al. · Investigational New Drugs · 2012 · 161 citations · Full text

Medicine, Oncology, Pharmacology +17

Semi-Mechanistic Pharmacokinetic/Pharmacodynamic Modeling of the Antitumor Activity of LY2835219, a New Cyclin-Dependent Kinase 4/6 Inhibitor, in Mice Bearing Human Tumor Xenografts

Sonya C. Tate, Shufen Cai, Rose T. Ajamie et al. · Clinical Cancer Research · 2014 · 127 citations · Full text

Medicine, Oncology, Pharmacology +16

A Novel CDK9 Inhibitor Shows Potent Antitumor Efficacy in Preclinical Hematologic Tumor Models

Tinggui Yin, Marı́a José Lallena, Emiko L. Kreklau et al. · Molecular Cancer Therapeutics · 2014 · 101 citations · Full text

Medicine, Cancer Biology, Oncology +13